CenterWatch

At CenterWatch, we aim to be the top destination for information on clinical trials, catering to both clinical research experts and patients alike. To fulfill this goal, we provide a variety of professional, educational, and informative services. These range from industry news and analysis to listings of clinical trials looking for volunteers. For further details, please explore the links below based on your interests. We offer numerous resources tailored specifically for patients. Our Clinical Trial Listing Service gives patients access to impartial information about clinical trials, featuring a comprehensive database with thousands of active studies. You can also find details about new medications and therapies. Additionally, CenterWatch offers health and educational materials related to clinical trials and various health topics.

National

English

Newspaper

Outlet metrics

Domain Authority

Ranking

Global

#368838

United States

#144413

Health/Biotechnology and Pharmaceuticals

#112

Traffic sources

Monthly visitors

Articles

Sponsors Face Fewer Financial Hits for Drug Delays Today, New Data Show

Aug 23, 2024 | centerwatch.com | James Miessler

The average daily cost for trials and drug development delays has dropped considerably for sponsors over the years, new data from the Tufts Center for the Study of Drug Development (CSDD) show, owing to a number of factors. The center’s latest Impact Report, which updates a number of outdated financial measures, is likely to be practicable for stakeholders from a strategic business perspective, says Ken Getz, executive director of Tufts CSDD.
Rare disease research: Small studies can have a large impact on medical knowledge

Jul 23, 2024 | centerwatch.com | Mike Ingram

Rare disease research: Small studies can have a large impact on medical knowledge Rare disease advocacy groups often use the phrase “rare is not rare” to drive home the point that although individual diseases and conditions might affect only a small number of people, together they constitute a large patient population. Another way of putting it, according to a 2023 paper published by researchers at the Mayo Clinic: “Rare diseases are individually rare but collectively common.”
New Report Addresses Trial Scarcity, Mapping Trial Distribution, County Demographics

Jul 15, 2024 | centerwatch.com | James Miessler

In an effort to improve access to clinical research in the US and ease enrollment challenges, the Milken Institute has published a new report focusing on distance as a barrier to trial participation, digging deep into demographics and distribution of trials across US counties, as well as offering an interactive map tool filterable by therapeutic area.
FDA Delivers Long-Anticipated Guidance on Diversity Action Plans

Jun 28, 2024 | centerwatch.com | James Miessler

By James Miessler The FDA has published overdue draft guidance on developing diversity action plans for clinical trials, moving the agency a step closer to the statutory mandate that all phase 3 trials include such plans.
EU Launches Two New Pilot Programs Amidst Activation of Transparency Regs

Jun 21, 2024 | centerwatch.com | James Miessler

The European Medicines Agency (EMA) is continuing efforts to improve trials in the trade bloc, announcing two new programs that will offer support on clinical trial applications as new transparency rules under its Clinical Trials Information System (CTIS) come into effect.
Sites May Be Underprepared for ICH E6 Revision, Survey Indicates

Jun 17, 2024 | centerwatch.com | James Miessler

Sites appear less informed and prepared than sponsors for the upcoming changes to the ICH E6 — Good Clinical Practices guideline, according to a newly published survey by Avoca, a WCG company. The greatly revised version of the international standard that has guided the clinical trials community since 1996, expected to be finalized this fall, includes many changes that would impact sites’ conduct of trials (The CenterWatch Monthly, Sept. 1, 2023).
Balance AI Potential with Unique Challenges, FDA Drug Policy Chief Says

Jun 7, 2024 | centerwatch.com | James Miessler

Recent years have shown AI’s potential for advancing drug development is undeniable, with hundreds of drug submissions to the FDA referencing AI solutions. But AI’s integration in trials must be balanced with careful considerations for a number of unique challenges, says M. Khair ElZarrad, director of the Center for Drug Evaluation and Research’s Office of Medical Policy.
Survey Shows Sites May Face Steep Learning Curve on ICH E6(R3)

May 17, 2024 | centerwatch.com | James Miessler

Adapting to the quality and risk management components embedded in the new ICH E6(R3) guidelines may present challenges for sponsors and providers, but it’s sites that may find the task particularly daunting, findings from an Avoca survey show. The 341-respondent survey conducted earlier this year focuses on sponsor, site and provider awareness of the new standards ICH E6(R3) presents and their perceived impact.
Warned for Unsecured Drug Storage, PI’s Corrective Plan Falls Short with FDA

May 10, 2024 | centerwatch.com | James Miessler

Precautions for securing a trial’s investigational drug(s) must be ironclad in the eyes of the FDA, and corrective and preventive actions enacted when these safeguards are absent or compromised must be just as rigorous, a recent FDA warning letter illustrates.
Mobile Trial Vans, Research Paramedics and More Featured in WCG Innovation Challenge

May 1, 2024 | centerwatch.com | James Miessler

Home » Mobile Trial Vans, Research Paramedics and More Featured in WCG Innovation Challenge The 2024 MAGI Clinical Research Conference in New Orleans played host to yet another exciting round of clinical trial innovation, with attendees voting on their favorite of five creative approaches in the WCG Innovation Challenge. Read on to learn more about this year’s winner as well as the four finalists.